Aimmune Therapeutics Inc  

(Public, NASDAQ:AIMT)   Watch this stock  
Find more results for AIMT
37.20
-1.04 (-2.72%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.99 - 38.66
52 week 15.97 - 40.65
Open 38.16
Vol / Avg. 0.00/437,329.00
Mkt cap 1.89B
P/E     -
Div/yield     -
EPS -2.34
Shares 50.86M
Beta     -
Inst. own 83%
Mar 13, 2018
Aimmune Therapeutics Inc at Cowen Health care Conference - 8:00AM EDT - Add to calendar
Jan 10, 2018
Aimmune Therapeutics Inc at JPMorgan Healthcare Conference
Dec 14, 2017
Aimmune Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Dec 1, 2017
Aimmune Therapeutics, Inc. - Special Call - Webcast
Nov 28, 2017
Aimmune Therapeutics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.05% -31.62%
Return on average equity -57.01% -32.84%
Employees 122 -
CDP Score - -

Address

8000 Marina Blvd Ste 300
BRISBANE, CA 94005-1884
United States - Map
+1-650-6145220 (Phone)
+1-650-6160075 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Officers and directors

Mark D. McDade Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stephen G. Dilly M.D. Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Jeffrey H. Knapp Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Susan E. Barrowcliffe Senior Vice President, General Manager of Europe
Age: 59
Bio & Compensation  - Reuters
Mary M. Rozenman Senior Vice President - Strategy and Corporate Development
Age: 36
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Sue Barrowcliffe General Manager of Europe
Bio & Compensation  - Reuters
Daniel C. Adelman M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Greg Behar Independent Director
Age: 47
Bio & Compensation  - Reuters